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The nucleus is a critical subcellular compartment
for the pathogenesis of polyglutamine disorders,
including Huntington’s disease (HD). Recent studies
suggest the first 17-amino-acid domain (N17) of
mutant huntingtin (mHTT) mediates its nuclear
exclusion in cultured cells. Here, we test whether
N17 could be a molecular determinant of nuclear
mHTT pathogenesis in vivo. BAC transgenic mice
expressing mHTT lacking the N17 domain (BACHD-
DN17) show dramatically accelerated mHTT pathol-
ogy exclusively in the nucleus, which is associ-
ated with HD-like transcriptionopathy. Interestingly,
BACHD-DN17 mice manifest more overt disease-
like phenotypes than the original BACHD mice,
including body weight loss, movement deficits,
robust striatal neuron loss, and neuroinflammation.
Mechanistically, N17 is necessary for nuclear exclu-
sion of small mHTT fragments that are part of
nuclear pathology in HD. Together, our study sug-
gests that N17 modifies nuclear pathogenesis and
disease severity in HD mice by regulating subcellu-
lar localization of known nuclear pathogenic mHTT
species.
INTRODUCTION
HD is the most common inherited neurodegenerative disease,
characterized by progressive movement disorders, psychiatric
symptoms, and cognitive impairment (Ross et al., 2014). Dis-
ease symptoms in HD are relentlessly progressive, and patients
usually die from disease complications about 20 years after
onset. HD neuropathology is characterized by brain atrophy,726 Neuron 85, 726–741, February 18, 2015 ª2015 Elsevier Inc.massive loss of striatal medium spiny neurons (MSNs), and, to
a lesser extent, loss of cortical pyramidal neurons (CPNs; Von-
sattel and DiFiglia, 1998). Moreover, modest atrophy in other
brain regions (e.g., cerebellum) has also been detected. Impor-
tantly, neurodegeneration in HD is accompanied by neuroin-
flammation (Moller, 2010) and signs of systemic inflammation
(Bjo¨rkqvist et al., 2008). The precise mechanisms underlying
the pathogenesis of neurodegeneration in HD remain poorly
understood.
HD is caused by a CAG repeat expansion encoding an elon-
gated polyglutamine (polyQ) repeat in the huntingtin protein
(HTT; The Huntington’s Disease Collaborative Research Group,
1993). HD belongs to a group of neurodegenerative disorders
caused by polyQ expansion (Orr and Zoghbi, 2007). These dis-
orders exhibit an inverse relationship between CAG repeat
length and age of disease onset, and for most of these disor-
ders, the mutant polyQ protein can misfold and form aggregates
in the brain. In HD, mutant huntingtin (mHTT) accumulates as
aggregates in both the cytosol and nucleus (DiFiglia et al.,
1997). The roles of polyQ protein aggregation in disease patho-
genesis appear complex, and there is evidence suggesting
certain aggregates may be neuroprotective (Orr and Zoghbi,
2007).
Studies of several polyQ diseases suggest that mutant pro-
teins may primarily elicit disease pathogenesis through toxicities
in the nucleus. In spinocerebellar ataxia 1 (SCA1) and spinal and
bulbar muscular atrophy (SBMA), blocking nuclear translocation
of mutant polyQ proteins abolishes disease pathogenesis in
mouse models (Klement et al., 1998; Katsuno et al., 2002).
Although HTT is predominantly located in the cytoplasm, it can
enter the nucleus under certain conditions (Atwal et al., 2011).
In HD, available evidence suggests that mHTT can elicit both nu-
clear and cytoplasmic pathogenesis (Ross and Tabrizi, 2011) and
form aggregates that consist of small mHTT polyQ fragments (Di-
Figlia et al., 1997; Lunkes et al., 2002). Studies suggest artificially
enhanced nuclear entry of mHTT polyQ fragments exacerbate
their toxicities in vivo (Benn et al., 2005; Gunawardena et al.,
Figure 1. Generation and Characterization
of BAC Mice Expressing DN17 Forms of
Huntingtin
(A) Schematic depicting transgene constructs
used in generating BACHD-DN17 and BAC-WT-
DN17 mice.
(B) Brain lysates of WT, BACHD, and BACHD-
DN17 mice were probed with anti-polyQ antibody
(1C2) to determine mHTT expression levels. The
anti-a-tubulin antibody was used for loading
control.
(C) BACHD-DN17 and BAC-WT-DN17 transgene
can rescue embryonic lethality of homozygous Htt
null mice. The panel shows the number of rescue
mice among the total number of mice born.
(D) An anti-HTT aa2-17 (PW0595A) antibody de-
tects the N17 domain of both human HTT and
murine Htt. The anti-polyQ antibody (1C2) detects
only human mHTT. Brain lysates of WT, BACHD,
BACHD-DN17, and BACHD-DN17/Htt/ mice
were probed with 1C2 and anti-N17 antibodies,
with anti-a-tubulin as loading control. See also
Figure S1.2003), but the endogenousmechanisms regulating nuclear-cyto-
plasmic trafficking of mHTT or its fragments in diseased brains
remain unclear.
The N-terminal 17-amino-acid domain (N17) of HTT, located
immediately preceding the polyQ domain, is an evolutionarily
conserved domain among vertebrates (Tartari et al., 2008). In
cultured cells, N17 canmediate both cytoplasmicmembrane as-
sociation (Rockabrand et al., 2007; Atwal et al., 2007) and Crm1-
dependent nuclear export of HTT N-terminal fragments (Maiuri
et al., 2013; Zheng et al., 2013), leading to predominantly cyto-
plasmic localization of these HTT species (Steffan et al., 2004).
Interestingly, the N17 domain can promote formation of oligo-
mers and aggregation of mHTT-exon1 fragments in vitro (Thakur
et al., 2009; Tam et al., 2009). Consistent with a role for this
domain in mHTT proteostasis, deletion of the N17 domain or
overexpression of its binding protein Tcp1 suppressesmHTT ag-
gregation in vitro and in cells (Tam et al., 2009; Omi et al., 2008;
Jayaraman et al., 2012). The N17 domain appears to be a regu-
latory hub for HTT, with more than ten known post-translational
modifications (PTMs) including phosphorylation, ubiquitination,
sumoylation, and acetylation (Lee et al., 2013). Among these,
the phosphorylation of serines 13 and 16 has been shown to
reduce oligomerization and aggregation of mHTT fragments
in vitro (Mishra et al., 2012), and phosphomimetic mutation of
these residues suppresses mHTT toxicity in cells, brain slices,
and in Bacterial Artificial Chromosome (BAC) HD mice (Gu
et al., 2009; Thompson et al., 2009; Atwal et al., 2011).
Although N17 phosphorylation has been implicated in modu-
lating mHTT toxicities in vivo (Gu et al., 2009), two important
N17 functions (i.e., influencing aggregation and nucleocytoplas-
mic trafficking of mHTT) have not been evaluated in vivo. In this
study, we created novel BAC transgenicmousemodels express-Neuron 85, 726–741,ing human mutant (97Q) or WT (31Q) HTT
with deletion of residues 2–16 in the N17
domain to evaluate the role of the N17domain in modifying mHTT-induced disease pathogenesis and
nuclear toxicities in vivo.
RESULTS
Generation of BAC Transgenic Mice Expressing DN17
Forms of Human Huntingtin
To create BAC transgenic mice expressingmutant andwild-type
(WT) human HTT lacking the N17 domain, we first confirmed that
deletion of residues 2–16 in N17 (DN17) in the context of WT
or mutant HTT exon1 abolished N17-mediated cytoplasmic
localization in transfected cells (Figures S1A and S1B). We
then engineered the human genomic BAC originally used to
create prior BACHD mouse models (Gray et al., 2008; Gu
et al., 2009) to express DN17 forms of mutant (DN17-mHTT-
97Q) or WT HTT (DN17-HTT-31Q; Figure 1A). These BACs
were microinjected into inbred FvB/N embryos to generate
transgenicmouse lines (N, L, and A lines) expressingDN17 forms
of mHTT (Figures 1B, S1C, and S1D). We also generated a con-
trol mouse line expressing DN17-HTT-31Q (BAC-WT-DN17).
Two of the three BACHD-DN17 lines (N and L) and the BAC-
WT-DN17 line express comparable levels of human HTT, as as-
sessed by western blots using a human-HTT-specific antibody
(Dehay et al., 2007; Figure S1C), as well as an expanded
polyQ-specific antibody (1C2; Figures 1B and S1C). The level
of human mHTT in BACHD-DN17 N line is about 25% that of
the original BACHD mouse line (Figure 1B) and estimated to be
about half the endogenous murine Htt level (Gray et al., 2008;
Gu et al., 2009). The BACHD-DN17 models are suitable to
assess, given the lower levels of mHTT expression, whether
they show accelerated or exacerbated disease pathogenesis
compared to BACHD. We focused our initial phenotypic studyFebruary 18, 2015 ª2015 Elsevier Inc. 727
Figure 2. Age-Dependent Motor Deficits
and General Health Decline in BACHD-
DN17 Mice
(A) Body weight of both male (M) and female (F)
BACHD-DN17 mice and WT mice from 1 month to
11 months of age. Significant interaction between
genotypes and age (F = 3.32, p < 0.01) for females
and age (F = 31.62, p < 0.001) for males was de-
tected (two-way ANOVA). Further Student’s t tests
at each age showed that both female and male
transgenic mice gained weight before 6 months
of age, before losing significant weight around
10monthsof age (*p<0.05, **p <0.01, ***p <0.001).
(B) Motor performance of BACHD-DN17 mice and
WT littermates was measured using an acceler-
ating rotarod test (**p < 0.01, ***p < 0.001, Stu-
dent’s t test).
(C) Gait analyses were performed at 2 months,
6 months, and 8 months of age (*p < 0.05, **p <
0.01, Student’s t tests).
(D) Spontaneous falls were counted in BACHD-
DN17 mice and WT littermates at 10 months of
age over a period of 180 s.
(E and F) BACHD-DN17 mice show unkempt fur
and urine scalding at 10 months of age (E) and lay
upside-down in the home cage (F). Data are
shown as mean ± SEM. Student’s t tests were
performed to compare the results of BACHD-
DN17 and WT mice (*p < 0.05; **p < 0.01; ***p <
0.001). See also Figures S2, S6, and S7.on the BACHD-DN17-N line (referred to hereafter as BACHD-
DN17), with key phenotypes found in this line then evaluated in
the other mouse lines.
N17 Domain Is Not Required for the Essential Function
of Huntingtin in Murine Development
Htt is essential for murine embryonic development (Zeitlin et al.,
1995), and BAC mice expressing full-length human mHTT or
mHTT with N17 phosphorylation site mutations can rescue the
lethality phenotype in Htt null mice (Gray et al., 2008; Gu et al.,
2009). To assess whetherDN17 forms of HTT still retain essential
HTT function during development, we crossed either BACHD-
DN17 or BAC-WT-DN17 transgenes onto the murine Htt null
background (Zeitlin et al., 1995) and found a Mendelian ratio of
rescued mice (Figures 1C and 1D) that are indistinguishable
from their WT littermates up to 2 months of age. This study dem-
onstrates that the N17 domain is not required for the essential
function of Htt during murine embryonic development and that
N17 deletion mutation does not appear to affect normal HTT
function in vivo.728 Neuron 85, 726–741, February 18, 2015 ª2015 Elsevier Inc.BACHD-DN17 Mice Exhibit Motor
and Psychiatric-like Behavioral
Deficits, Weight Loss and General
Health Decline
We next evaluated a cohort of BACHD-
DN17 andWT littermates up to 11months
of age for motor phenotypes and health
status. We first evaluated body weight in
these mice. Interestingly, both male andfemale transgenic mice are slightly heavier than WT at 2 and
6 months of age, similar to other HD transgenic mice overex-
pressing human HTT (Gray et al., 2008). However, unlike BACHD
mice, but similar to HD patients (Ross et al., 2014), BACHD-
DN17 mice exhibit significant weight loss at 10 months and
11 months of age compared to WT (Figure 2A).
We next evaluated BACHD-DN17 mice for motor coordination
using the accelerating rotarod test. The transgenic mice have
normal rotarod performance at 1 month of age (p = 0.625, Stu-
dent’s t test) but exhibit progressive impairment at 2 and
6 months of age (Figure 2B; two-way ANOVA, age and genotype
interaction, p < 0.0001; age, p < 0.0001; genotype, p = 0.005),
similar to BACHD (Gray et al., 2008;Wang et al., 2014). However,
unlike BACHD, which can still run rotarod at a compromised level
at 12 months of age, BACHD-DN17 mice can no longer run ro-
tarod by 8 months of age (Figure 2B), suggesting that BACHD-
DN17 mice exhibit more severe motor deficits than BACHD.
We next evaluated spontaneous locomotion using the open
field test (Wang et al., 2014). BACHD-DN17mice showed normal
locomotion at 2 months of age but exhibit significant impairment
in horizontal distance traveled (two-way ANOVA, genotype and
age interaction, p = 0.0028; genotype, p = 0.0229), horizontal
speed, and vertical plane entry (rearing) at 8 months of age (Fig-
ures S2A–S2C; two-way ANOVA, genotype and age interaction,
p < 0.0001; genotype, p < 0.0001).
HD patients exhibit psychiatric symptoms (Ross et al., 2014),
and BACHD mice also show psychiatric-like behavioral deficits
(Wang et al., 2014). Similar to BACHD, the BACHD-DN17 mice
show significantly increased immobility in the forced swim test
compared to WT mice at 5 months of age (Figure S2D, p <
0.001, Student’s t test, n = 10 per genotype), suggesting the
presence of depression-like behaviors in these mice.
Gait abnormalities are common in HD patients and can lead to
substantial morbidity (Ross et al., 2014). Impressively, BACHD-
DN17 mice show normal gait parameters at 2 months and mini-
mal deficits at 6 months but significant gait abnormalities at
8 months of age (Figure 2C). Severe gait impairment in HD pa-
tients often results in spontaneous falls (Grimbergen et al.,
2008), a phenotype not reported in previous HD mouse models
(Crook and Housman, 2011). To our surprise, starting around
10months of age, BACHD-DN17 but notWTmice show frequent
spontaneous falls (Movie S1; Figure 2D). Consistent with pro-
gressive neurological decline in this model, BACHD-DN17 but
not WTmice at 10 to 11 months of age are frequently found lying
upside down in their home cage, poorly groomed and with
discoloration of fur due to urine scalding (Figures 2E and 2F;
Movie S1).
Since BACHD-DN17 mice exhibit HD-like progressive motor
impairment and health decline, which are either more severe
than or absent in BACHD mice, we conclude that BACHD-
DN17 mice exhibit more severe disease-like phenotypes than
BACHD.
BACHD-DN17 Mice Exhibit Adult-Onset Overt
Movement Deficits and Aberrant Striatal Neuronal
Activities
A clinical hallmark in HD is adult-onset movement disorder,
including chorea and dystonia (Ross et al., 2014), a phenotype
that has largely been absent in previousHDmousemodels (Crook
and Housman, 2011). When we observed 11-month-old mice, we
were surprised to find that BACHD-DN17 but not WT mice show
frequent abnormal head movements consisting of smooth but
non-rhythmic side-to-side swinging of the head and upper
body, reminiscent of choreiform movement, and also sustained
retroflex of head and neck lasting up to a few seconds, reminis-
cent of cervical dystonia (Figure 3A;Movies S1 and S2). The onset
of abnormal head movements in BACHD-DN17 mice is age
dependent and progressive. These movements are absent in
transgenicmice at 5months of age (Movie S3), have onset around
7 months of age, and progressively increase in frequency by
roughly 10-fold between 7 and 10 months (Figure 3B; Movie
S4). These phenotypic characteristics appear to have some
face validity for the overt movement disorder manifested in HD,
and hence we refer to the abnormal movement in BACHD-
DN17 mice as Chorea/Dystonia-Like (CDL) movement deficits.
Abnormal head-tossingmovements,whichareassociatedwith
cortical spike-wave epilepsy, have been shown in mice with
mutated voltage-dependent calcium channels (Burgess andNoebels, 1999). However, using synchronized video monitoring
and cortical local field potential recording in 5-hr-long sessions
with 7- to 9-month-old BACHD-DN17 mice, we did not observe
any epileptic activity during the entire recording period, despite
frequent CDLs seen in the mutant mice (Figure 3C). Interestingly,
local field potential recordings in the cortex and dorsal striatumof
BACHD-DN17 mice revealed synchronous, short duration (100–
200 ms), large-amplitude events in the low gamma range (25–
55 Hz; Figure 3E; data not shown), while WT littermates showed
only minor gamma activity (Figure 3D). This finding is consistent
with prior observation of increased low gamma frequency events
in the striatum of other HD mouse models (e.g., Cayzac et al.,
2011). To investigate whether the abnormal striatal gamma fre-
quency activity in the BACHD-DN17 mice is progressive, we re-
corded younger transgenic mice (16–18weeks of age) and found
that the mutant mice already show significant differences in
gamma frequency events from WT littermates (Kolmogorov-
Smirnov test, p = 0.0078), but importantly such differences pro-
gressively worsen with age (Kolmogorov-Smirnov test, p =
5.831011; Figures 3F and 3G). Our study shows that CDLs are
not due to cortical epileptic activity and are associated with an
age-dependent increase in the abnormal striatal gamma fre-
quency activities in BACHD-DN17 mice.
Selective Cortical and Striatal Atrophy, Striatal Neuron
Loss, and Reactive Gliosis in BACHD-DN17 Mice
HD neuropathology is characterized by selective cortical and
striatal atrophy with massive striatal neuronal cell loss, but
modest atrophy of other brain regions, such as the cerebellum
(Vonsattel and DiFiglia, 1998). Existing HD mouse models often
recapitulate the brain atrophy but lack robust striatal neuron
loss (Crook and Housman, 2011). We evaluated BACHD-DN17
mice for HD-like neurodegeneration phenotypes. The transgenic
mice have similar forebrain weight compared toWT littermates at
2 months, but at 6–10 months of age BACHD-DN17 mice show
progressive and significant forebrain weight loss (Figure 4A;
two-way ANOVA, genotype and age interaction, p < 0.0001; ge-
notype, p = 0.0039; age, p < 0.0001). Impressively, at 10 months
of age, BACHD-DN17 mice have 34% forebrain weight loss
compared to WT. Moreover, the brain atrophy in BACHD-DN17
is relatively selective, since the cerebellum shows only modestly
significant weight loss at 10 months of age and not younger (Stu-
dent’s t test, p < 0.05; Figure 4A). We next performed unbiased
stereology and found significant cortical (p < 0.005, Student’s
t test) and striatal (p < 0.001, Student’s t test) volume loss in 10-
month-old BACHD-DN17 mice compared to WT littermates (Fig-
ure 4B). Importantly, using stereological counting of DARPP-32
immunoreactiveMSNs,we found thatBACHD-DN17mice exhibit
robust loss of striatalMSNs (about 40%) at 10months of age (Fig-
ure 4C; n = 5 per genotype, p < 0.001, Student’s t test). Finally,
since neurodegeneration in HD caudate/putamen is accompa-
nied by reactive gliosis (Vonsattel and DiFiglia, 1998), we exam-
ined BACHD-DN17 striatum and cortex at 10 months of age
and found reactive astrocytes with elevated GFAP expression
and hypertrophic processes (Figures 4D–4G). We conclude that
BACHD-DN17 mice exhibit progressive HD-like neurodegenera-
tive pathology, including relatively selective cortical and striatal
atrophy, striatal MSN loss, and reactive gliosis.Neuron 85, 726–741, February 18, 2015 ª2015 Elsevier Inc. 729
Figure 3. Progressive Chorea/Dystonia-like Movement Deficits and Aberrant Striatal Neuronal Activities in BACHD-DN17 Mice
(A) Composited image depicting chorea/dystonia-like (CDL) head movement in BACHD-DN17 mouse.
(B) Quantification of CDLs in 3 min of video recording. Two-way ANOVA reveals significant difference between BACHD-DN17 and WT littermates in age and
genotype interaction: F = 16.55, p < 0.0001; phenotype: F = 117.2, p < 0.0001. Data are shown as mean ± SEM.
(C) Cortical field potential recording showing no epileptic activity during chorea-like movement (horizontal box over the recording) in an 8-month-old BACHD-
DN17 mouse.
(D) There is no significant gamma activity in the dorsal striatum of WT littermates. Middle: local field potential recording in the dorsal striatum of a WT littermate.
Top: corresponding wavelet transform shows minor activity in the low gamma band (20–50 Hz). Bottom: enlarged segments of the field potential recordings
indicated by dashed boxes.
(E) Frequent gamma events in BACHD-DN17 mice. From top second row: local field potential recording in the dorsal striatum. Top: corresponding wavelet
transform shows transient increments in the gamma range. Third row: sample large gamma events, enlarged segments of the local field potential recording
indicated by dashed boxes with the corresponding wavelet transform (bottom).
(F and G) Progression of the large gamma events in the striatumwith aging in BACHD-DN17mice. Cumulative probability plot of inter-event interval in younger (F)
and older (G) animals. Red, transgenic; black, wild-type; thicker lines indicate the corresponding pooled cumulative probability. See also Movies S1, S2, S3, S4,
and S5 and Figures S6 and S7.
730 Neuron 85, 726–741, February 18, 2015 ª2015 Elsevier Inc.
Figure 4. Progressive and Selective Brain
Atrophy, Striatal Neuron Loss, and Gliosis
in BACHD-DN17 Mice
(A) Weight of the forebrain and cerebellum of
BACHD-DN17 and WT littermates was measured
at 2, 6, 8, and 10 months of age. Progressive
forebrain weight loss is detected in BACHD-DN17
mice starting at 6 months of age and progresses
between 6 months and 10 months of age. Two-
way ANOVA reveals significant differences be-
tween HD-DN17 and WT littermates in age and
genotype interaction (F = 49.94, p < 0.0001; ge-
notype: F = 173.2, p < 0.0001). No weight loss is
detected in the cerebellum until 10 months of age.
(B) Unbiased stereological measurement of brain
regions was performed to measure cortical and
striatal volume in BACHD-DN17 mice and WT
littermates.
(C) Unbiased stereological counting revealed
robust loss of Darpp32+ neurons in 10-month-old
BACHD-DN17 mice compared to WT controls.
(D–G) Reactive astrogliosis is detected in striatum
and deep cortical layers of BACHD-DN17 mouse
brain with GFAP immunohistochemical staining
(E and G). No such gliosis is seen in control mouse
brain (D and F). Data are shown as mean ± SEM.
Student’s t tests were performed to compare
BACHD-DN17 and WT samples (*p < 0.05; **p <
0.01; ***p < 0.001). Scale bar, 100 mm. See also
Figures S3, S6, and S7.BACHD-DN17Mice Exhibit HD-like Peripheral Pathology
HD is characterized by certain peripheral pathology, such as
muscle atrophy and testicular degeneration (van der Burg
et al., 2009). To assess peripheral pathology, we evaluated the
weights of multiple peripheral organs and tissues in BACHD-
DN17 and WT mice at 10 months of age (Figures S3A–S3C).
Importantly, the weights of multiple peripheral organs (i.e., heart,
spleen, kidney, and liver) in the transgenic mice are similar to WT
mice at this relatively advanced disease stage (Figure S3A), sug-
gesting the toxicity elicited by DN17-mHTT is not ubiquitous. We
next evaluated the BACHD-DN17 mice for the testicular degen-
eration phenotype of HD (Van Raamsdonk et al., 2007), finding
marked testicular atrophy in the mutant mice (Figure S3B) asso-
ciatedwith age-dependent infertility starting at around 5months.Neuron 85, 726–741,Finally, BACHD-DN17 mice also show
quadriceps muscle pathology (Figures
S3D–S3G), including significant atrophy,
reduction of muscle fiber caliber, and
aberrant central localization of nuclei
within the fiber (Sopher et al., 2004).
These results show that BACHD-DN17
mice recapitulate several aspects of pe-




A marker of HD neuropathology is the
presence of aggregated mHTT polyQfragments in the nucleus and cytoplasm (DiFiglia et al., 1997).
Using two humanmHTT-exon1-specific antibodies that are sen-
sitive to aggregated mHTT (S830 and EM48; Sathasivam et al.,
2001; Gutekunst et al., 1999), we characterized patterns of
mHTT aggregation in BACHD-DN17 mice (Figure 5). We did
not detect any mHTT aggregates in 2-month-old transgenic
brain sections. At 4 months of age, BACHD-DN17 mice show
diffusemHTT nuclear staining, aswell as small nuclear inclusions
(NIs), in the cortex but rarely in the striatum (Figures 5A and 5B).
At 6 months and older, BACHD-DN17 mice show both diffuse
nuclear staining and prominent nuclear inclusions (NIs) in both
cortex and striatum (Figures 5A and 5B). Interestingly, mHTT ag-
gregates are exclusively found in the nucleus, with cytoplasmic
aggregates not found in the transgenic mice (Figures 5C andFebruary 18, 2015 ª2015 Elsevier Inc. 731
Figure 5. Deletion of N17 Selectively Accelerates mHTT Nuclear
Accumulation and Aggregation in BACHD-DN17 Mouse Brains
(A and B) Immunohistochemistry with EM48 (A) and S830 (B) antibodies to
detectmHTT nuclear accumulation and aggregation in 2-, 4-, and 6-month-old
BACHD-DN17 mouse cortex and striatum.
(C) Immunofluorescent staining to simultaneously detect S830+ mHTT ag-
gregates (green), NeuN+ neurons (red), and merged signals with DAPI nuclear
staining (yellow and purple).
(D) Immunofluorescent staining to simultaneously detect S830+ mHTT ag-
gregates (green), Ubiquitin+ nuclear inclusions (red), and merged signals with
DAPI nuclear staining (yellow and purple). Scale bar, 50 mm. See also Figures
S4, S6, and S7.5D). Moreover, nuclear mHTT aggregate pathology can also be
found in other brain regions at 6 and 10 months of age, including
the hippocampus, thalamus, cerebellum, and brain stem (Fig-
ure S4). Double immunofluorescent staining showed that732 Neuron 85, 726–741, February 18, 2015 ª2015 Elsevier Inc.mHTT aggregates are almost exclusively in NeuN+ neurons in
the striatum (Figure 5C) and that the NIs are also immunoreactive
for ubiquitin (Figure 5D), a pathological feature similar to HD
(DiFiglia et al., 1997) but absent in BACHD mice (Gray et al.,
2008; data not shown). Our result demonstrates that N17 is a
critical determinant of the rate and subcellular localization of
mHTT aggregate pathology in vivo.
Evidence Supports Selective Requirement of N17 to
Mitigate Nuclear Translocation and Aggregation of
Small mHTT PolyQ Fragments
To obtain biochemical evidence that N17 is crucial for nuclear
exclusion of mHTT in vivo, we performed subcellular fraction-
ation of nuclear and cytoplasmic protein extracts from 1- and
10-month-old BACHD, BACHD-DN17, and WT control mice
(Figures 6A–6C). Prior studies in transfected cells suggest that
certain N17 mutations (e.g., M8P) can lead to increased nuclear
translocation of fragment or full-length HTT (Atwal et al., 2007),
suggesting N17 may be required for cytoplasmic targeting of
all HTT species. To our surprise, we found that in both 1- and
10-month-old mouse forebrains, the soluble DN17-mHTT (full-
length mHTT lacking only residues 2–16) is distributed almost
exclusively in the cytosol, a pattern similar to full-length mHTT
in BACHD (Figure 6A). Interestingly, at 10 months but not at
1 month of age, high molecular weight (HMW) mHTT species
accumulate exclusively in the nucleus of BACHD-DN17 mice
but not in BACHD or WT controls (Figure 6A). Similar mHTT
HMW species have been found in brains of HD patients and
mouse models (DiFiglia et al., 1997; Landles et al., 2010; Lunkes
et al., 2002). Consistent with the notion that such HMW mHTT
species are aggregated mHTT N-terminal fragments, we found
that they can be detected with antibodies against mHTT-exon1
epitopes (Figure 6A), but cannot be stained with an antibody
against a C-terminal HTT epitope (Figure 6B; Shirasaki et al.,
2012). Moreover, by using formic acid to dissociate the nuclear
mHTT aggregates (Lunkes et al., 2002), we found that nuclear
aggregates in BACHD-DN17 mice appear to consist predomi-
nantly of two small mHTT polyQ fragments of around 55 kDa
(Figure 6C). Thus, our biochemical analyses provide strong
evidence that the absence of N17 in the context of otherwise
full-length mHTT results in a dramatic acceleration of nuclear
accumulation and aggregation of small mHTT N-terminal frag-
ments in vivo.
To further explore the discrepancy between the in vitro (Thakur
et al., 2009; Tam et al., 2009) and our in vivo findings on the
impact of N17 on the rate of mHTT aggregation, we used a
cell-based FRET assay in transfected primary neurons to study
the difference between intact N17 andDN17 inmodifying the ag-
gregation of mHTT-exon1 (Zheng et al., 2013). Consistent with
prior in vitro studies, we found that overall levels of aggregation
were significantly reduced in the DN17 mutants compared to
mHTT-exon1 with intact N17 (Figures S5A and S5B). However,
similar to our in vivo finding, deletion of N17 leads to significantly
increased nuclear aggregation (Figure S5C).
Since our studies showed that full-length mHTT does not
require N17 for its predominant cytoplasmic localization in vivo,
we next asked what sizes of mHTT N-terminal polyQ fragments
are dependent on N17 for their nuclear exclusion, at least in
Figure 6. N17-Dependent Nuclear Accumulation of mHTT In Vivo and In Vitro
(A and B)Western blot analysis of cytosolic and nuclear fractions from the forebrain extracts from 1- and 10-month-oldWT, BACHD, and BACHD-DN17mice. The
blots were probed with antibodies against (A) the N-terminal human mHTT-exon1 (S830) and (B) the C-terminal HTT (MAB7667; Shirasaki et al., 2012). Lamin B1
and a-tubulin served as loading controls for nuclear and cytosolic fractions, respectively.
(C) Nuclear (N) and cytosolic (C) extracts of forebrains from 1- and 10-month-old WT, BACHD, and BACHD-DN17 were treated with 100% formic acid to dissolve
the SDS-insoluble mHTT aggregates (Lunkes et al., 2002), followed by western analysis. For better detecting the presence of mHTT fragments shown in lanes
5–8, mHTT was immunoprecipitated and detected by an anti-polyQ antibody (1C2).
(D) HEK293 cells were transfected with plasmids carrying mHTT fragments of different sizes, i.e., Exon1, CpA (N114), Caspase 6 (N586), and either with (left) or
without (right) N17 (deletion of amino acid residues 2–16). All constructs of fragments were fused at C-terminal with HA-tag and are as labeled on the images. The
subcellular localization of mHTT was revealed by immunostaining of the HA-tag and imaged by confocal microscopy.
(E) The nuclear and cytosolic distribution of mHTT fragments in (D) was quantified based on an established protocol (Ch’ng et al., 2012). The ratios of
mean intensity of nuclear and cytosolic fluorescent signals of individual cells were plotted and analyzed using Student’s t test. Data are shown as mean ± SEM.
***p < 0.001; scale bar, 20 mm. See also Figure S8.cultured cells. We focused on three mHTT fragments that have
been implicated in HD pathogenesis: the caspase 6 (C6) frag-
ment, consisting of the N-terminal 586 amino acid residues of
mHTT (Graham et al., 2006); CpA fragment, with N-terminal
114 residues (Lunkes et al., 2002); and exon1 (Sathasivam
et al., 2013). Importantly, both CpA and exon1 fragments havebeen shown to be part of mHTT nuclear aggregate pathology
in HD (Lunkes et al., 2002; Landles et al., 2010). We generated
plasmid constructs overexpressing these mHTT-46Q fragments
either with or without N17 and transiently transfected them into
HEK293 cells (Figure 6D). By quantifying the ratio of nuclear
versus cytoplasmic mHTT fragment signals in the transfectedNeuron 85, 726–741, February 18, 2015 ª2015 Elsevier Inc. 733
Figure 7. Progressive HD-like Transcriptional Dysregulation and WGCNA Analyses of Gene Expression Profiles in BACHD-DN17 Striatum
(A) Heatmap representing differentially expressed genes at different ages in the striatum of BACHD-DN17 compared toWTmice. Upregulated genes are shown in
red and downregulated genes in green; color intensity corresponds to fold change in expression.
(B) Venn diagrams representing the overlap between genes previously reported as dysregulated in HD patients (Kuhn et al., 2007, left circles) and genes
dysregulated in the BACHD-DN17 model (this study, right circles). An increasing degree of overlap between the two datasets is observed in both upregulated
(red numbers) and downregulated (green numbers) genes as the BACHD-DN17 animals age (p = hypergeometric test).
(legend continued on next page)
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cells (Ch’ng et al., 2012; Figure 6E), we found that the C6 frag-
ments either with or without N17 are located predominantly in
the cytoplasm, but both the mHTT-exon1 and CpA fragments
appear to depend on N17 for nuclear exclusion, since deletion
of N17 in these fragments leads to a significant increase in their
nuclear localization (Figures 6D and 6E). Together, our study pro-
vides the initial evidence that N17 appears to be selectively
required for nuclear exclusion of certain small mHTT fragments
that are known to be nuclear pathogenic in HD.
Phenotypic Characterization of Additional
BACHD-DN17 and BAC-WT-DN17 Mouse Lines
We next studied additional BACHD-DN17 mouse lines to
ensure key phenotypes in BACHD-DN17 mice are reproducible
in independent lines. The BACHD-DN17-L line, with compara-
ble DN17-mHTT expression levels as BACHD-DN17 (Figures
S1C and S1D), exhibits significant body weight loss at 5 months
of age (Figure S6A). These mice show more aggressive dis-
ease, with premature lethality at around 5 months of age (Fig-
ure S6B). Importantly, BACHD-DN17-L mice also show CDLs
starting at 4–5 months of age (Figure S6C; Movie S5) and fore-
brain weight loss with modest cerebellar weight loss (Fig-
ure S6D). Finally, immunostaining of cortical and striatal sec-
tions reveals robust mHTT nuclear aggregation in transgenic
but not WT mice (Figure S6E; data not shown). Thus, multiple
disease features of BACHD-DN17 are reproduced in the L
line mice.
A thirdBACHD-DN17mouse line thatwe have analyzed is theA
line. These mice express very little DN17-mHTT, which is not
detectable in the soluble fraction but can be detected as a faint
band in the insoluble fraction (Figure S6F). Interestingly, the A
line mice appear indistinguishable from WT littermates until
18 months of age, when they show significant body weight loss
(Figure S6G), abnormal and progressive CDLs (Figure S6H), and
significant forebrain and cerebellar atrophy (Figure S6I). More-
over, mHTT aggregate pathology is absent at 6 months but
progressively increases between 18 and 24 months in the A line
mice (Figure S6J). Together, our study suggests that a very small
amount of DN17-mHTT is sufficient to elicit multiple disease-like
features in vivo, albeit with much later age of disease onset.
Finally, we analyzed BAC-WT-DN17 mice that express DN17-
HTT-31Q at a level comparable to BACHD-DN17 (Figures S1C
and S1D). The transgenic mice do not show body weight loss
by 12 months of age (Figure S7A), nor any brain or organ atrophy
up to 19 months of age (Figures S7B and S7C). The transgenic
mice are comparable to WT littermates in rotarod testing (Fig-
ure S7D) and do not exhibit CDLs (Movie S6) up to 12 months
of age. Finally, the transgenic mice do not show nuclear HTT pa-
thology by 12 months (Figures S7E and S7F). Thus, we conclude(C) Cluster dendrogram generated by hierarchical clustering of probes on the ba
were identified using a dynamic cutting algorithm, and color-coded modules (blu
(D and E) Heatmap and first principal component of expression data for genes
coordinated changes in gene expression within these two modules.
(F and G) Enrichment analyses indicate overrepresentation of neuronal genes a
turquoise module, and of gene transcripts related to neuroinflammation, includin
(H and I) Network visualization of the turquoise and blue modules with top hubs hi
HD caudate (Hodges et al., 2006) are depicted in purple. Genes involved in AD athat HD-like phenotypes elicited by DN17 forms of mHTT are
polyQ-length dependent.
Gene Expression Profiling and Network Analyses Reveal
HD-like Transcriptional Profiles and Progressive
Neuroinflammation in BACHD-DN17 Striatum
A molecular signature of mHTT nuclear pathogenesis is tran-
scriptional dysregulation (Hodges et al., 2006; Ross and Tabrizi,
2011). To assess whether accelerated nuclear mHTT accumula-
tion in BACHD-DN17 mice could also induce transcriptional sig-
natures similar to HD, we usedmicroarrays to profile progressive
striatal gene expression changes in BACHD-DN17 and WT con-
trol mice. We identified a set of time-dependent gene expression
changes when comparing BACHD-DN17 and WT mice at 2, 7,
and 11 months (Table S1). We then compared the gene expres-
sion profile in BACHD-DN17 striatum with that observed in the
postmortem HD caudate/putamen (Hodges et al., 2006; Kuhn
et al., 2007) and found a progressive overlap for both down-
and upregulated genes (Figure 7A). This overlap was significant
at 7 months and 11 months, but not 2 months (Figure 7B; hyper-
geometric test), suggesting that BACHD-DN17 mice exhibit pro-
gressive HD-like transcriptionopathy.
To further illuminate the molecular networks dysregulated in
the longitudinal transcriptional profiles from the BACHD-DN17
and WT brains, we analyzed our entire gene expression dataset
usingWeighted Gene Coexpression Network Analysis (WGCNA;
Zhang and Horvath, 2005). This analysis allows the identification
of highly co-expressed gene groups (modules) and their central
hubs (the most connected genes in the module), and its applica-
tion to both normal and diseased brain transcriptomes is highly
informative in identifying gene networks and in helping generate
novel hypotheses (Geschwind and Konopka, 2009). WGCNA
identified seven main modules, ranging between 63 and 3,247
probes in size (Figure 7C; Table S1). To facilitate visualization
and analysis of these modules, we have created an interactive
network web browser (see Experimental Procedures). We corre-
lated the consensus gene expression pattern within each
module (‘‘module eigengene’’ or ME; Oldham et al., 2008), with
genotype and age, and identified two modules with consistent
genotype- and age-dependent changes in gene expression.
The turquoisemodule (Figures 7D, 7F, and 7H) revealed a cluster
of 3,247 genes that are unchanged in WT striatum at 2, 7, and
11 months of age but are progressively reduced in expression
at 7 and 11 months in BACHD-DN17 striatum. The 2,141 genes
in the blue module (Figures 7E, 7G, and 7I) showed the opposite
pattern, with WT unchanged over time and age-dependent pro-
gressive increase in the BACHD-DN17 striatum.
Gene set enrichment analysis (Miller et al., 2011) of the
turquoise module (Figure 7F) shows significant enrichmentsis of topological overlap. Seven modules of highly co-expressed transcripts
e, red, green, turquoise, brown, and pink, respectively).
in the turquoise and blue modules identified age and genotype-dependent,
nd genes implicated in other brain disorders (e.g., schizophrenia, AD) in the
g microglia and astrocyte markers, in the blue module.
ghlighted (inner circle). Genes already shown to have transcriptional changes in
nd frontotemporal dementia (e.g., Grn) are depicted in red.
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of neuron-specific genes, glutamatergic synapse transcripts,
genes enriched in the human/chimp caudate, and genes
changed in R6/2 HDmice and HD patients (Figure 7F; Woodman
et al., 2007). This module contains many of the well-known MSN
marker genes that are downregulated in HD caudate/putamen,
including Drd2, Drd1, Gpr6, Actn2, Pde10a, Adora2a, Ppp1r1b
(Darpp-32), Cnr1, and Rgs9 (Figure 7H; Table S2). The downre-
gulation of multiple turquoise module genes was confirmed by
quantitative RT-PCR (Figure S8A) and by quantifying immuno-
stained brain sections to assess protein levels (i.e., Drd2 and
Drd1; Figures S8B–S8D). This latter finding suggests that tur-
quoise module genes do not simply reflect the loss of striatal
MSNs in the BACHD-DN17 mice, but also neuronal dysfunction,
since the surviving MSNs show reduction of dopamine receptor
levels.
Importantly, the hub genes in the turquoise module highlight
novel candidates that may be relevant to striatal MSN dysfunc-
tion and degeneration in the BACHD-DN17 model (Figure 7H).
The top hub gene in turquoisemodel isActinin-2, a post-synaptic
density (PSD) protein enriched in the striatum and cortex (Dunah
et al., 2000) that complexes with NMDA receptors (Wyszynski
et al., 1997). Our recent study revealed that striatal Actn2 reduc-
tion in BACHD striatum is due to both non-cell-autonomous
toxicities of cortical mHTT as well as cell-autonomous toxicities
of striatal mHTT (Wang et al., 2014). Examples of other
turquoise module hub genes that could be candidates to study
their roles in HD pathogenesis include, but are not limited to,
Pde10a, Pde2a, Dcamkl1, Gabrd, Cacng4, Ddit4l, Ryr1, Igfbp4,
Ntrk3, Gpr6, Rxrg1, and Rarb (Figure 7H).
Blue module genes are progressively upregulated in BACHD-
DN17, but notWT striatum. Gene set enrichment analysis reveals
a significant over-representation of genes specific for astrocytes,
microglia, and oligodendrocytes (Figure 7G). We also confirmed
the upregulation of several blue module genes in aged BACHD-
DN17 striatum using quantitative RT-PCR (Figure S8A). Consis-
tentwith the interpretation that theBluemodule consists of genes
involved in progressive neuroinflammation, the module contains
well-known marker genes involved in reactive astrocytosis
(e.g., GFAP and S100a6; Figures 4D–4G) and microgliosis (e.g.,
Lgals3/Mac-2, Tspo, and CD68; Figure 7I; Table S2; Moller,
2010). To confirm the presence of progressive microgliosis in
theBACHD-DN17micebetween 6 and10months of age,weper-
formed immunostaining for Lgals3 (Mac-2/Galectin-3), a marker
protein that is selectively upregulated in activated microglia dur-
ing brain injury and neurodegenerative disease (e.g., Alzheimer’s
disease, [AD]; Rotshenker, 2009). We found that Lgals3 staining
is apparent only in BACHD-DN17 but not WT striatum at
11 months of age and is restricted to Iba1+ microglia with
hypertrophic (reactive) morphology (Figures S8E–S8K), and
the number of Lgals3+ cells progressively increases in BACHD-
DN17 striatum between 6 and 11 months of age.
Since the blue module is enriched in genes involved in neuro-
inflammation, it is interesting to note that multiple genes in the
module are also upregulated in the cortex of early AD, with
some being AD risk genes (e.g., ApoE, Trem2, Abca7, Ms4a6d,
and Grn; Figures 7G and 7I; Karch et al., 2014). In particular,
we found a marked overlap of Blue module hub genes with the
recently defined hub genes for the Bayesian Brain Immune and736 Neuron 85, 726–741, February 18, 2015 ª2015 Elsevier Inc.Microglia gene modules for late-onset AD (Figure 7I; Table S2;
Zheng et al., 2013). These shared hub genes include comple-
ment cascade genes (e.g., C1qa, C1qb, C3, Tyrobp, CD33),
toll-like receptor signaling genes (e.g., Tlr2,Myd88, CD86), che-
mokine/cytokine genes (e.g., Cx3cr1, Il17ra), and Fc-receptor
system genes (e.g., Trem2, S100a11, Apoc1, Serpina1). The
intriguing overlap of neuroinflammatory transcription signatures
between BACHD-DN17 striatum and AD suggests that this
model could be useful to study disease-associated neuroinflam-
matory genes that may be shared between HD and other neuro-
degenerative disorders.
DISCUSSION
In summary, we have generated and characterized novel BAC
transgenic mice expressing mutant or WT human HTT lacking
the N17 domain to evaluate the impact of this domain in regu-
lating mHTT nucleocytoplasmic trafficking, aggregation, and
disease pathogenesis in vivo. We showed that BACHD-DN17
mice exhibit earlier onset and more severe disease phenotypes
compared to BACHD mice. Importantly, BACHD-DN17 mice
show multiple HD-like disease phenotypes (e.g., CDLs, robust
striatal MSN loss, and neuroinflammation) that are not observed
in previous HD mouse models. Mechanistically, our study re-
veals the important function of the N17 domain in mitigating nu-
clear pathogenesis elicited by small mHTT polyQ fragments
in vivo.
Our study provides novel insight into N17 domain function
in vivo. The N17 domain is evolutionarily conserved in the verte-
brate lineage (Tartari et al., 2008), suggesting it may confer
conserved functions for HTT among vertebrates. Our study
shows that BAC transgenes expressing mutant or WT HTT lack-
ing N17 domain can rescue the embryonic lethality phenotype of
murine Htt null mice, suggesting the N17 domain is not required
for the essential HTT function during murine development. Our
study, together with prior genetic evidence (Neveklovska et al.,
2012; Zheng et al., 2010), suggests that essential embryonic
developmental functions of HTT in vertebrates do not appear
to require the three domains near the HTT N terminus (i.e., the
N17, polyQ, and polyproline domains). It would be tempting to
speculate that these HTT exon1 domains, which co-evolved
within the vertebrate lineage (Tartari et al., 2008), could be
sub-serving a function of HTT that is specific to mature organ-
isms, possibly within the nervous system. One hint of this func-
tion may come from a study where mice expressing Htt lacking
the polyQ domain show enhanced neuronal autophagy and
longevity (Zheng et al., 2010).
Our study reveals N17 as a critical molecular determinant of
mHTT-induced nuclear pathogenesis in vivo. Although prior
cell-based studies have demonstrated that the N17 domain con-
fers cytoplasmic membrane association (Rockabrand et al.,
2007; Atwal et al., 2007) and nuclear export of mutant and WT
HTT (Maiuri et al., 2013; Zheng et al., 2013), these studies were
done in the context of small HTT fragments (i.e., exon1) and in
transfected cells, hence the impact of N17 in regulating mHTT
subcellular trafficking in the context of full-length mHTT and dis-
ease pathogenesis in vivo remained yet unexplored. Our study
provides crucial evidence that BAC mice expressing mHTT
that lacks the N17 domain, despite lower level expression of
mHTT than the BACHD model, show dramatic acceleration of
mHTT aggregation (4 months in BACHD-DN17 versus 11–
12months in BACHD). Moreover, the pattern of mHTT pathology
is also drastically different between the twomodels, with BACHD
showing predominantly cytoplasmic mHTT aggregates (Gray
et al., 2008), while BACHD-DN17 show exclusively nuclear
mHTT aggregates. These results demonstrate a pivotal in vivo
function of N17 domain in regulating mHTT proteostasis in the
nuclear and cytoplasmic compartments, suggesting that com-
promising N17 function can dramatically accelerate nuclear
pathogenesis in HD mouse brains.
Extensive prior studies suggest that generation of mHTT
N-terminal fragments by proteolysis (DiFiglia et al., 1997) or alter-
native splicing (Sathasivam et al., 2013) may be an important
mechanism in eliciting nuclear pathogenesis in HD (Ross and
Tabrizi, 2011). Perhaps the best evidence supporting this idea
is that aggregated mHTT species isolated from neuronal nuclei
in HD patients or mice are small mHTT fragments, including
exon1 (Landles et al., 2010) and CpA fragments (Lunkes et al.,
2002). Moreover, transgenic mice expressing mHTT polyQ frag-
ments exhibit exacerbated disease and increased mHTT nuclear
pathology compared to those models expressing full-length
mHTT (Crook and Housman, 2011; Li et al., 1999). However,
an intriguing set of studies shows that the soluble mHTT-exon1
in transgenic mouse brains is predominantly cytoplasmic, even
when the fragment is fused with an exogenous nuclear localiza-
tion signal (Benn et al., 2005), suggesting that additional molec-
ular element(s) may be involved in regulating the nuclear patho-
genesis of mHTT fragments. Our current study suggests that
N17 could function in the context of small mHTT fragments to
mitigate their potential in eliciting nuclear pathogenesis in vivo.
Our in vivo biochemical analyses reveal that the aggregated
nuclear mHTT species in BACHD-DN17 brains consist predom-
inantly of two small mHTT polyQ fragments, while the intact sol-
uble full-length DN17-mHTT is always cytoplasmic (Figure 6).
This latter finding is somewhat surprising, since point mutations
in N17 (i.e., M8P), in the context of full-length HTT, have been
shown to increase nuclear translocation in transfected cells
(Atwal et al., 2007). Moreover, our cell-based study provides
initial support for a selective requirement of N17 to mediate nu-
clear exclusion of small mHTT fragments (e.g., exon1 and CpA)
that are known to be nuclear pathogenic in HD (Lunkes et al.,
2002; Landles et al., 2010), but not for larger mHTT fragments
(e.g., C6). Given the limitation of our current study using a trans-
fected non-neuronal cell line to study N17 dependency in nuc-
leocytoplasmic trafficking of various mHTT fragments, future
studies should validate and extend such observations into pri-
mary neuronal cells and into WT and HD mouse brains.
Based on the phenotypic findings of BACHD-DN17 mice and
our mechanistic insights that N17 appears to preferentially act
on smaller mHTT fragments to mediate their nuclear exclusion,
we would like to propose the following model of how N17 may
regulate nuclear pathogenesis in HD (Figure 8). In HD neurons,
full-length or fragmented mHTT species are predominantly
located in the cytoplasm and may contribute to cytoplasmic
pathogenesis. For nuclear pathogenesis to occur, two events
are likely needed. First, the generation of small mHTT fragments(e.g., exon1 or CpA), which are at baseline protected from nu-
clear translocation or accumulation by N17. Moreover, N17
may also promote their cytoplasmic clearance and suppress
their toxicities through protective PTMs (Steffan et al., 2004;
Thompson et al., 2009; Gu et al., 2009). Thus, for nuclear patho-
genesis to occur, we speculate that a second event would be
required to impair the N17 function in mediating nuclear export
and cytoplasmic membrane association of the mHTT fragments.
This may involve either functional impairment (i.e., intact, but
non-functional N17, such as N17-mediated oligomerization or
aggregation; Jayaraman et al., 2012) or physical impairment of
this domain (e.g., deleterious PTMs; N17 truncation). One impor-
tant possibility in our model is that the accumulated nuclear
mHTT species may be a mixture of those with intact N17 and
those with physically impaired N17, which may help to explain
the presence of N17 epitope in at least some of the nuclear
mHTT species in HD brains (DiFiglia et al., 1997). We acknowl-
edge that future studies are needed to rigorously test this hypo-
thetical model. This may require detailed proteomic analyses of
the mHTT species accumulating in the nuclei of HD patients or
mouse models and elucidation of the molecular mechanisms
that regulate N17-mediated HTT nucleocytoplasmic trafficking
in both normal and diseased brains.
Our study also provides important evidence that the N17
domain can act as a bidirectional molecular switch to modify
the severity of disease elicited by full-length mHTT in HD mice.
Using the same human genomic transgenic constructs express-
ing mHTT with the same polyQ length, differing only in the N17-
coding regions, we have previously shown that BAC mice
expressing mHTT with phosphomimetic mutations at serines 13
and 16 abolish all the disease phenotypes found in BACHD, sug-
gesting that promoting these N17 PTMs may suppress disease
pathogenesis in vivo (Gu et al., 2009). Our current study showed
that deletion of the N17 domain in the same BAC transgenic HD
model system leads to dramatic exacerbation of disease pheno-
types, including worsening rotarod deficits, body weight loss,
robust striatal neurodegeneration and neuroinflammation, and
the emergence of new HD-like phenotypes that are not seen in
other HDmousemodels (e.g., CDLs, spontaneous falls, and urine
scalding). Importantly, BACHD-DN17 mice also show peripheral
pathology reminiscent of HD (van der Burg et al., 2009). Together,
our study reveals that deletion of N17 in the context of the BAC
transgenic HD model system results in more severe, yet still
HD-like disease phenotypes in vivo. Despite the improved face
validity of BACHD-DN17 mice compared to prior HD mouse
models, such as BACHD, we are cognizant that this model has
limitations in terms of construct validity (i.e., deletion of 15 amino
acid residues in the N17 domain of mHTT). We believe the
BACHD-DN17 model may offer new opportunities to study as-
pects of disease elicited by mHTT (e.g., nuclear pathogenesis,
mHTT proteolysis, striatal neuronal degeneration and neuroin-
flammation). Moreover, our in vivo insights gained from HD
BAC mice with N17 mutations suggest the importance of eluci-
dating themolecular bases for the bidirectional diseasemodifica-
tions conferred by N17 mutations and exploration of molecular
targets interacting with this crucial domain for HD therapy.
Finally, from a translational research perspective, BACHD-
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Figure 8. A Working Model of N17 Domain Role in Regulating Nuclear Pathogenesis in HD
In HD neurons, full-length or fragmented mHTT species are predominantly located in the cytoplasm due to N17 function in Crm1-dependent nuclear export and
cytoplasmic membrane association. For nuclear pathogenesis to occur, two events are likely needed to occur. First, the generation of small mHTT N-terminal
fragments (e.g., mHTT-exon1 or CpA), which are known to be part of nuclear mHTT pathology in HD brains. Since these small mHTT fragments have functional
N17, they are located predominantly in the cytoplasm, where N17 can facilitate their clearance (Thompson et al., 2009). The various mHTT species can also elicit
cytoplasmic pathogenesis. For nuclear pathogenesis to occur, N17 domain on the small mHTT fragments has to be impaired either functionally (e.g., oligo-
merization or aggregation of mHTT fragments in the nucleus) or physically (e.g., deleterious N17 PTMs or truncation/proteolysis of N17 itself). Future studies are
needed to determine whether N17 impairment can be demonstrated among the nuclear accumulated mHTT species in HD patients or mouse models. Moreover,
the molecular pathways that may regulate N17 function in nucleocytoplasmic trafficking and whether manipulating these pathways could modify nuclear mHTT
pathogenesis and overall disease phenotypes in HD models or HD remain to be elucidated.the interplay between age-dependent neurodegeneration and
neuroinflammation in neurodegenerative disorders. Emerging
evidence suggests that neuroinflammation may play a key role
in many, if not all, major neurodegenerative disorders (Glass
et al., 2010). Previous HD mouse models exhibit limited neuroin-
flammation, not approaching the extent seen in HD patients
(Moller, 2010). Importantly, our longitudinal transcriptome
profiling and subsequent validation studies showed that
BACHD-N17 mice exhibit age-dependent neuroinflammation
that partially overlaps that seen in both HD and AD and includes
causal or risk allele genes involved in AD (e.g., ApoE,
Trem2, Abca7,Ms4a4, and Clu) and FTD genes (e.g.,Grn; Karch
et al., 2014). These findings underscore potential common
neuroinflammatory mechanisms between our mouse model
and multiple neurodegenerative disorders and suggest that
BACHD-DN17 mice could be an invaluable in vivo paradigm to
study molecular and cellular interactions between degenerating738 Neuron 85, 726–741, February 18, 2015 ª2015 Elsevier Inc.neurons and reactive glia, as well as to test candidate therapeu-
tics against neurodegeneration or neuroinflammation.
EXPERIMENTAL PROCEDURES
Transgene Constructs and Generation of BACHD-DN17 and
BAC-WT-DN17 Mice
HTT BAC DNA modification was performed as previously reported (Yang
et al., 1997; Gu et al., 2009). The modified BAC constructs were confirmed
by sequencing before being microinjected into FvB/NJ fertilized oocytes at
the UCLA Transgenic Core to generate BACHD-DN17 and BAC-WT-DN17
mice. Transgenic mice were bred and maintained under standard condi-
tions consistent with NIH guidelines, and all procedures complied with reg-
ulations and approved by the UCLA Institutional Animal Care and Use
Committees.
Quantitation of Transgene Expression
Three brain extracts from the transgenic mouse lines were used for mHTT
quantification by western blot with mHTT specific antibody, MAB5492 (against
human HTT polyproline domain; EMD Millipore; Dehay et al., 2007), 1C2, and
a-tubulin as reported previously (Gu et al., 2009).
Behavioral Tests and Quantifications
Quantitation of chorea/dystonia-like (CDL) behavior, rearing, and spontaneous
falling of eachmousewasmanually calculated for the last 3min of a 5min video
clip (details see Supplemental Experimental Procedures). Accelerating rotarod
test was performed at 1, 2, 4, 6, and 8months of age, and automated open field
testing was performed at 2, 4, and 8 months of age with established protocols
(Gray et al., 2008;Wang et al., 2014). Gait impairment testing was performed at
2, 6, and 8 months of age. All tests used over ten mice. The investigators were
blinded to the genotypes when performing these behavioral tests.
Electroencephalography
Synchronous video-EEG recordings were carried out at least 7 days after sur-
gery in freely moving mice in an 8-inch diameter recording chamber. Field po-
tential recordings were band-pass filtered and amplified (0.3 Hz–1 kHz, gain:
1,000, Model 3500, A-M Systems), digitized on-line at a rate of 2048 s-1
(PCI-MIO16E-4 data acquisition board National Instruments), and acquired
continuously (SignalExpress, National Instruments). All data analysis was per-
formed under IGOR Pro v6.22A. Morlet wavelet analysis was performed for
time-frequency analysis of local field potential recordings.
Analysis of Fragment Size-dependent Subcellular Distribution
of mHTT
HEK293 cells were transfected with DNA constructs of mHTT (46Q) fragments
fused with a HA-tag (see Supplemental Information) for 48 hr. The expression
and localization of mHTT fragments was probed with an antibody against the
HA-tag, followed by an Alexa 488 conjugated secondary antibody. Hoechst
33258 (Sigma) was used to visualize nuclei. Confocal images were analyzed
by ImageJ (NIH) using an established method (Ch’ng et al., 2012). In brief,
the fluorescence intensity of the nuclear and cytosolic mHTT fragments was
quantified and the ratio of the mean intensity of nuclear/cytosolic signal was
calculated. Student’s t test was used to measure the statistical significance.
Microarray and Data Analysis
Microarray processing was performed by the UCLA Neuroscience Genomics
Core (UNGC, http://www.semel.ucla.edu/ungc). The transcription profiling
dataset in this study is available at GEO (GSE64386). Enrichment analysis
was performed using the collapseRows and userListEnrichment functions in
R as described (Miller et al., 2011; http://www.inside-r.org/packages/cran/
WGCNA/docs/userListEnrichment). We have made the WGCNA networks
and associated gene-level data available for the top 500 connections in
each module in an online interactive browser (https://coppolalab.ucla.edu/
gclabapps/nb/browser?id=Yang_HD_STR;ver). For methods and data anal-
ysis in detail, see Supplemental Experimental Procedures.
Statistical Analyses
Western blot quantification statistical analysis was determined by one-way
ANOVA, followedbyTukey’sMultipleComparison post hoc test. For electroen-
cephalograph data, statistical analysis was performed using the Kolmogorov–
Smirnov test. Significance was set to p < 0.05. To determine significant main
effects and interactions between main factors, two-way ANOVA was used to
evaluate the effects of time and genotype followed by post hoc tests using
the Bonferroni method. When appropriate, differences between genotype
means were evaluated with unpaired Student’s t test. Overlap between gene
sets was assessed using the hypergeometric test in R (function phyper), using
the number of shared gene symbols between array platforms as background.
All data are expressed as mean ± SEM. Significance level was p < 0.05. Prism
software was used to conduct these analyses (Graphpad). Detailed Experi-
mental Procedures can be found in Supplemental Experimental Procedures.
ACCESSION NUMBERS
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